In vitro and in vive biochemistry of olanzapine: A novel, atypical antipsychotic drug

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 10, 1997, Pages 28-36

  Bymaster, Frank P ^a   Rasmussen, Kurt ^a   Calligaro, David O ^a   Nelson, David L ^a   DeLapp, Neil W ^a   Wong, David T ^a   Moore, Nicholas A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERGOLIDE MESILATE; QUETIAPINE; RISPERIDONE; ADRENERGIC RECEPTOR; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR; DRUG DERIVATIVE; MUSCARINIC RECEPTOR; NEUROTRANSMITTER RECEPTOR; PIRENZEPINE; SEROTONIN RECEPTOR;

AGRANULOCYTOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHO CELL; COGNITIVE DEFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; MONKEY; NEGATIVE SYNDROME; NONHUMAN; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; ANIMAL; CHEMISTRY; CLINICAL PHARMACOLOGY; DRUG DESIGN; DRUG EFFECT; HAMSTER; HAPLORHINI; HUMAN; IN VITRO STUDY; RAT; REVIEW;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHEMISTRY, PHARMACEUTICAL; CRICETINAE; DRUG DESIGN; HAPLORHINI; HUMANS; PHARMACOLOGY, CLINICAL; PIRENZEPINE; RATS; RECEPTORS, ADRENERGIC; RECEPTORS, CHOLINERGIC; RECEPTORS, MUSCARINIC; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, SEROTONIN;

EID: 0030841409     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Crow TJ. Molecular pathology of schizophrenia: more than one disease process. BMJ 1980;280:66-68
2. Ellenbroek BA. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 1993;57:1-78
3. Meltzer HY. The mechanism of action of clozapine in relation to its clinical advantages. In: Novel Antipsychotic Drugs. Meltzer HY, ed. New York, NY: Raven Press; 1992:1-13
4. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992;160(suppl 17):41-45
5. Davis JM, Caspar R. Antipsychotic drugs: clinical pharmacology and therapeutic use. Drugs 1974;14:260-282
6. Tarsey D. Neuroleptic-induced extrapyramidal reactions: classification, description and diagnosis. Clin Neuropharmacol 1983;6:S9-S26
7. i values. J Pharmacol Exp Ther 1989;251:238-246
8. Kane JM, Honigfeld G, Singer J, et al, and the Clozaril Collaborative Group. Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial. Psychopharmacology 1989;99:S60-S63
9. Helmchen H. Clinical experience with clozapine in Germany. Psychopharmacology 1989;99:S80-S83
10. Fitton A, Heel RC. Clozapine: a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990;40:722-747
11. Kane JM, Honigfeld G, Singer J, et al, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-796
12. Clozapine 1994. J Clin Psychiatry 1994;55(9, suppl B)
13. Hippius H. The history of clozapine. Psychopharmacology 1989;99:S3-S5
14. Class F. Drug-induced agranulocytosis: review of possible mechanisms, and prospects for clozapine studies. Psychopharmacology 1989;99: S113-S117
15. Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 1992;160(suppl 17):38-40
16. Chakrabarti JK, Horsman L, Hotten TM, et al. 4-piperazmyl-10H-thieno [2,3-b][1,5]benzodiazepines as potential neuroleptics. J Med Chem 1980; 23:878-884
17. Beasley CM, Tollefson GD, Tran P, et al and The Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol: acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacologv 1996;14:111-123
18. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14:87-96
19. 2 binding affinity. Neuropsychopharmacology 1988;1:101-107
20. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 1989;99:S18-S27
21. Moore NA, Calligaro DO, Wong DT, et al. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993;2:281-293
22. Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991;43:587-604
23. Pancheri P. Neuroleptics and 5-HT receptors: a working hypothesis for antipsychotic effects. N Trends Exp Clin Psychiatry 1991;7:141-150
24. 7 receptors. J Pharmacol Exp Ther 1994;268:1403-1410
25. Bartholini G. Interactions of striatal dopaminergic, cholinergic and GABA-ergic neurons: relation to extrapyramidal function. Trends Pharmacol Sci 1980;1:138-140
26. 3 receptors is not shared by its two major metabolites and by structurally related and un-related atypical neuroleptics. Naunyn Schmiedebergs Arch Pharmacol 1996;353:290-294
27. Sanchez C, Arnt J, Dragsted N, et al. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 1991;22:239-250
28. Skarsfeldt T. Electrophysiological profile of the new atypical antipsychotic neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse 1992;10:25-33
29. Migler BA, Warawa EJ, Malick JB. Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology 1993;112:299-307
30. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:185-292
31. Leysen JE, Gommeren W, Eens A, et al. Biochemical profiles of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988;247:661-670
32. Roose K, Gelders Y, Heylen S. Risperidone (R 64 766) in psychotic patients: a first clinical therapeutic exploration. Acta Psychiatr Belg 1988; 88:233-241
33. Lewander T, Westerbergh SE, Morrison D. Clinical profile of remoxipride: a combined analysis of a comparative double-blind multi-centre trial programme. Acta Psychiatr Scand 1990;82(suppl 358):92-98
34. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-113
35. Moore NA, Tye NC, Axton MS. et al. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-551
36. 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 1996; 124:87-94
37. Zorn SH, Jones SB, Ward KM, et al. Clozapine is a potent and selective muscarinic m4 receptor agonist. Eur J Pharmacol 1994;269:R1-R2
38. Dragunow M, Robertson GS, Faull RLM, et al. D2 dopamine receptor antagonists induce fos and related proteins in rat striatal neurons. Proc Natl Acad Sci USA 1992;89:4270-4274
39. Deutch AY, Lee MC, Iadarola MJ. Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 1992;3:332-341
40. 2 receptor blockade to haloperidol. Neurosci Lett 1995;194:77-80
41. Robertson GS, Fibiger HC. Ncuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992;46:315-328
42. Berman KF, Weinberger DR. The prefrontal cortex in schizophrenia and other neuropsychiatric diseases: in vivo physiological correlates of cognitive deficits. In: Uylings HBM, VanEden CG, DeBrun JPC, et al, eds. Progress in Brain Research, vol 85. Amsterdam, The Netherlands: Elsevier Science: 1990:521-537
43. Robertson GS, Fibiger HC. Effects of olanzapine on regional C-Fos expression in rat forebrain. Neuropsychopharmacology 1996;14:105-110
44. Robertson GS, Matsumara H, Fibiger HC. Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994;271:1058-1066
45. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbram dopaminergic neurons. J Neurosci 1983;3:1607-1619
46. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983;221: 1054-1057
47. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996;14:97-104
48. Farde L, Nordstrom A, Wiesel F, et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992;49:538-544
49. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology 1995;117:55-61
50. 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology 1996;124:148-153
51. 2 and D2 receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. In press
52. Nyberg S, Nakashima Y, Nordstrom A, et al. Positron emission tomography of in vivo binding characteristics of atypical antipsychotic drugs. Br J Psychiatry 1996;168(suppl 29):40-44
53. Wainscott DB, Lucaites BL, Kursar JD, et al. Pharmacologic characterization of the human 5-hydroxytryptamine-2B receptor: evidence for species differences. J Pharmacol Exp Ther 1996;276:720-727
54. Schotte A, Janssen PFM, Gommeren W. et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73
55. Fuller RW, Snoddy HD. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine, an antipsychotic drug candidate. Research Communications in Chemical Pathology and Pharmacology 1992;77:87-93
56. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995;281:289-294
57. Moore NA. Leander JD, Benvenga MJ. et al. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 1997;58(suppl 10);37-44
58. Tollefson GD. Concluding remarks. J Clin Psychiatry 1997;58(suppl 10):73
59. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997;58(suppl 10):7-12